Sartorius Stedim Biotech S.A. Investor Relations

A Trusted Partner for the Biopharmaceutical Industry and Laboratories

Sartorius Stedim Biotech is a leading international partner for the biopharma sector. Our solutions are supporting our customers to develop and produce drugs safely, timely and economically. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies.

Seven reasons to invest

  • Clear focus on the attractive biopharma sector
  • Long-term growth drivers and significant market entrance barriers
  • Market leading position in key technologies and recognized brand
  • High share of recurring revenue as well as diversified earnings base
  • Strong presence in growth regions
  • Proven track record with alliances and acquisitions
  • High continuity with respect to customer base, employees and management

Sartorius Stedim Biotech | Three-Month 2020 Results

  • Sales revenue up 22.3% in constant currencies, order intake up 39.3%, underlying EBITDA margin1 up 1.4 percentage points to 30.0%
  • Strong demand across all product categories and geographies; additionally fueled by significant equipment orders from China and customer stocking initiatives
  • Outlook for 2020 increased and adjusted for imminent closing of acquisition of Danaher life science assets and for pandemic-related effects

Earnings Release 

Conference Call Presentation

Conference Call Audio

Acquisition News

Sartorius Stedim Biotech closes acquisition of selected assets of Danaher Life Sciences.

Aubagne, France, April 30, 2020

Press Release 

Strategy and Targets for 2025

Sartorius Stedim Biotech’s goal is to continue its profitable growth and systematically expand its position as a leading international partner for biopharmaceutical research and the industry. We are pursuing various strategic initiatives to grow sustainably up to 2025 – and beyond.

  • Achieve consolidated sales revenue of around 2.8 billion euros
  • Increase underlying EBITDA margin1) to around 30%

1) Sartorius Stedim Biotech uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization; adjusted for extraordinary items) as the key profitability indicator.

We focus in both divisions on the attractive biopharmaceutical market characterized by long‑term and stable growth trends.

Key Growth Drivers

  • Growing world population
  • Increasing incomes and better access to healthcare services in emerging economies
  • Aging population and rise in age-related diseases in industrialized countries

Medical progress is also fueling growth, resulting in the ongoing development and approval of new biopharmaceuticals and in the improvement or expansion of indications for already existing active pharmaceutical ingredients. Therefore, a growing number of biotech medications are being approved for treatment of rare diseases considered incurable until now, and innovative cell and gene therapies are projected to further drive growth in the biopharma sector.

Sartorius Stedim Biotech has leading market positions in core technologies and is continuously expanding its portfolio by new, complementary technologies that help our biopharma customers develop and manufacture medications faster and more easily. Our strength in selecting suitable partners or acquisition candidates is based upon our in-depth understanding of applications. We are thoroughly familiar with our customers’ requirements and their entire value-added chains, and particularly understand the interactivity of the systems they use. Our innovation strategy is based on three pillars:

  • Integration of innovations through acquisitions
  • Alliances with partners
  • Own product development

North America and selected countries in Asia are at the focus of our growth strategy.

North America is the world’s largest market for both the development and the manufacture of biopharmaceuticals. Because North America is home to the main competitors for both company divisions, Sartorius Stedim Biotech has historically lower market shares in this region than in Europe and Asia. Accordingly, the company is striving to gain market share, primarily by strengthening its sales and service capacities.

Our second regional focus is on Asia, especially on China, South Korea and India. These markets have tremendous growth potential due to their increased healthcare spending by private households and governments. In these regions, Sartorius Stedim Biotech has invested in its sales infrastructure and is planning to expand its production capacities.

Moreover, we are investing in the digitalization of our processes. In addition, we have substantially expanded our production capacities, above all for filter and bag products.

"The impact of the corona pandemic on the healthcare sector and the biopharmaceutical industry should be much smaller than on most other industries. However, because of the various restrictions that are in place in most countries at the moment and will continue in the foreseeable future, our forecast is subject to somewhat greater uncertainty than usual. This concerns both the development of the existing product segments and the integration of the acquired businesses,” said Joachim Kreuzburg.

Based on first-quarter results and in connection with the upcoming closing of the acquisition of select life science assets from Danaher, SSB has adjusted its forecast for the full year of 2020. This forecast is based on the scenario that the Danaher portfolio acquired will be included as of May 2020.

For fiscal 2020, management now projects sales revenue to increase by 17% to 21% (before: 11% to 14%). The non-organic contribution from Biological Industries is still expected to be 2 percentage points, while the portfolio acquired from Danaher is expected to contribute about 3 percentage points. With respect to profitability, the company's underlying EBITDA margin1 is expected to rise to 30.0% (before: 29.5%; previous year: 29.3%) including a slightly dilutive effect through the acquired businesses. The CAPEX ratio1 is projected to be around 8% (forecast unchanged; previous year: 9.4%). Net debt to underlying EBITDA1 is now expected to amount to approx. 0.5 at year-end (before: slightly below 0.3; 0.3 as of Dec. 31, 2019).

All forecast figures are based on constant currencies, as in the past years.


1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving the comparability of business performance over time and within the industry.

  • Underlying EBITDA: earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items
  • Order intake: all customer orders contractually concluded during the respective reporting period
  • Underlying net profit: profit for the period after non-controlling interest; adjusted for extraordinary items and non-cash amortization, as well as based on a normalized financial result and tax rate
  • Underlying earnings per share: relevant net profit for the period divided by the number of shares outstanding (92,180,190)
  • CAPEX ratio: investment payments in relation to sales revenue for the same period. 

Sartorius Stedim Biotech S.A. is the parent company of the Sartorius Stedim Biotech Group. It is headquartered in Aubagne, France, and listed on the Euronext Paris.


Approximately 74% of the share capital and around 85% of the voting rights of Sartorius Stedim Biotech S.A. are held by Sartorius AG. Sartorius AG is a leading international bioprocess and laboratory equipment and technology provider headquartered in Göttingen, Germany, and listed on the Frankfurt Stock Exchange. It operates two divisions: the bioprocess business as a subgroup under its parent corporation Sartorius Stedim Biotech S.A. and the laboratory business as a further subgroup.

About Sartorius Stedim Biotech
Learn More

Documents

Investors Presentation Q1 2020 Results

PDF 2.1 MB

Sartorius Stedim Biotech Online Annual Report

Learn More

IR Factsheet Q1|2020

PDF 88.8 KB

Downloads

First-Quarter Results January to March 2020

April 21, 2020

Full-Year 2019 Results

February 18, 2020

Financial Publications
Learn More

Get in Touch

Petra Kirchhoff
Head of Corporate Communications & Investor Relations
Ben Orzelek
Head of Investor Relations

Financial Calendar

Financial Calendar
Learn More

Top News Sartorius Stedim Biotech

Annual Shareholders' Meeting on June 24, 2020 – Update on voting...

Sartorius Stedim Biotech S.A. will convene a video-based Combined Annual Shareholders’ Meeting (ASM) for Wednesday, June 24, 2020, at 10:00 a.m.

Read More

Sartorius Stedim Biotech closes acquisition of selected assets of...

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of selected life science...

Read More

Sartorius Stedim Biotech with a strong start in 2020

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, has continued on its profitable growth track in the first quarter...

Read More

More Information

Newsroom

Learn More

Facts & Figures

Learn More

Investor Relations Sartorius AG

Learn More